PCI and PACT Host AI Event for Philly Tech Week
PCI and the Philadelphia Alliance for Capital and Technologies (PACT) jointly presented a recent event called “AI Nexus: Shaping Tomorrow’s Intelligence."
A Rare Patient Mutation May Help Lead to More Effective Treatments for Genetic Bone Disease
Davis' relatively benign symptomology is attributed to low levels of the inflammatory protein MMP-9, which seems to prevent the characteristic abnormal bone formation.
Penn Researchers Create Novel mRNA-based Avian Flu Vaccine
Penn Medicine researchers have developed an mRNA vaccine for the H5N1 avian flu using techniques similar to those enabling mRNA-based COVID-19 vaccines.
EU Approves Expanded Use of Sobi’s Aspaveli® for Rare Blood Disorder
The European Commission has approved Sobi's drug Aspaveli® (pegcetacoplan) for broader use in adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder.
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, Appoints Eugene P. Kennedy as Chief Medical Officer
Carisma announced the dosing of its first patient in its Phase 1 trial for CT-0525, an innovative CAR-Monocyte therapy targeting HER2-overexpressing solid tumors.
Verismo Therapeutics Receives FDA Clearance for Phase I Trial of its CAR-T Therapy
Penn spinout Verismo Therapeutics has received FDA clearance for a Phase I trial of its CAR-T therapy, SynKIR-310.
iEcure Receives Three FDA Designations for its In Vivo Gene Insertion Program
iEcure, a gene-editing company spun out of Penn and co-founded by Dr. Wilson, has received three special designations from the FDA for its new treatment, ECUR-506.
Penn’s CAR-T Treatment Shrank Brain Tumors in Patients in Clinical Trial
In a new early-stage clinical trial, a Penn-invented CAR-T treatment shrank brain tumors in seven patients with glioblastoma.
Penn Spinout Capstan TherapeuticsRaises $175M in Series B Financing Round
Proceeds from the financing will be used to advance Capstan's lead in vivo chimeric antigen receptor T cell (CAR-T) candidate, CPTX2309, to early clinical proof-of-concept in autoimmune disorders.
iEcure Gains FDA approval to Conduct FirstGene Therapy Treatment
Utilizing ARCUS, a gene editing tool developed by Precision BioSciences, the therapy aims to provide a lifelong fix for this disease, potentially benefiting thousands of individuals in the US alone.